ALKERMES | ALKS - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 740M 40M 2025-06
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 12.28M 7.63M 2025-12
Amgen USD 653M 32M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Coherus Biosciences USD 2.15M 3.2M 2025-03
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 255M 1000K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 18M 0 2025-12
J&J USD 18M 290M 2025-09
Merck USD 412M 85M 2025-12
Minerva Neurosciences USD 2.31M 60K 2024-06
Nektar Therapeutics USD 6.02M 420K 2024-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Otsuka Holdings JPY 2.21B 866M 2025-12
Ovoca Bio EUR 7K 6K 2022-06
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12